Medicare covers inpatient and outpatient care for skin cancer. People with Original Medicare parts A and B or Medicare Advantage plans can expect extensive coverage, but they will likely have out ...

Medicare has chosen 15 prescription medications for price negotiations this year, building off a first round of negotiations for 10 drugs whose lower prices take effect in 2026. T

The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.

Most health insurance providers and Medicare cover Gentle Cure. Medicare Part A covers radiation therapy when you are receiving inpatient treatment in the hospital. Part B covers radiation therapy for outpatients or for those receiving treatment at a freestanding clinic.

WASHINGTON — Medicare officials announced plans to negotiate the prices of blockbuster diabetes and weight loss drugs Ozempic and Wegovy, further complicating big decisions the Trump administration will have to make about how to cover the medications.

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.

The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts before President-elect Trump’s inauguration. The Centers for Medicare

The hugely popular medications Ozempic and Wegovy​, used for diabetes and weight loss, will be included in the next round of talks to negotiate lower Medicare drug prices.

Guardant Health, Inc. (NASDAQ:GH) announced that Palmetto GBA, a Medicare administrative contractor that administers the Molecular Diagnostics Services program (MolDX), granted coverage for the Guardant Reveal test to monitor for disease recurrence in patients with colorectal cancer (CRC) following curative intent therapy.

Given forthcoming changes to Medicare Part D plans under the Inflation Reduction Act, CMS should collect and publish plan-level metrics describing how beneficiaries’ use of medications is impacted by formulary composition.

An analysis of oncology drugs approved in the United States found that Medicare spending was predominantly driven by the market, not a drug’s therapeutic value.

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.